These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 36008808)

  • 1. Development and evaluation of uncertainty quantifying machine learning models to predict piperacillin plasma concentrations in critically ill patients.
    Verhaeghe J; Dhaese SAM; De Corte T; Vander Mijnsbrugge D; Aardema H; Zijlstra JG; Verstraete AG; Stove V; Colin P; Ongenae F; De Waele JJ; Van Hoecke S
    BMC Med Inform Decis Mak; 2022 Aug; 22(1):224. PubMed ID: 36008808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population Pharmacokinetics and Dosing Optimization of Piperacillin-Tazobactam in Critically Ill Patients on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy.
    Hahn J; Min KL; Kang S; Yang S; Park MS; Wi J; Chang MJ
    Microbiol Spectr; 2021 Dec; 9(3):e0063321. PubMed ID: 34937189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Piperacillin penetration into tissue of critically ill patients with sepsis--bolus versus continuous administration?
    Roberts JA; Roberts MS; Robertson TA; Dalley AJ; Lipman J
    Crit Care Med; 2009 Mar; 37(3):926-33. PubMed ID: 19237898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of continuous infusion of piperacillin in critically ill patients.
    Dhaese SAM; Roberts JA; Carlier M; Verstraete AG; Stove V; De Waele JJ
    Int J Antimicrob Agents; 2018 Apr; 51(4):594-600. PubMed ID: 29277531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Individualization of piperacillin dosing for critically ill patients: dosing software to optimize antimicrobial therapy.
    Felton TW; Roberts JA; Lodise TP; Van Guilder M; Boselli E; Neely MN; Hope WW
    Antimicrob Agents Chemother; 2014 Jul; 58(7):4094-102. PubMed ID: 24798288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Saturable elimination of piperacillin in critically ill patients: implications for continuous infusion.
    Dhaese SAM; Colin P; Willems H; Heffernan A; Gadeyne B; Van Vooren S; Depuydt P; Hoste E; Stove V; Verstraete AG; Lipman J; Roberts JA; De Waele JJ
    Int J Antimicrob Agents; 2019 Dec; 54(6):741-749. PubMed ID: 31479741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Piperacillin Population Pharmacokinetics in Critically Ill Adults During Sustained Low-Efficiency Dialysis.
    Kanji S; Roberts JA; Xie J; Alobaid A; Zelenitsky S; Hiremath S; Zhang G; Watpool I; Porteous R; Patel R
    Ann Pharmacother; 2018 Oct; 52(10):965-973. PubMed ID: 29730948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Piperacillin Population Pharmacokinetics and Dosing Regimen Optimization in Critically Ill Children Receiving Continuous Renal Replacement Therapy.
    Thy M; Urien S; Foissac F; Bouazza N; Gana I; Bille E; Béranger A; Toubiana J; Berthaud R; Lesage F; Renolleau S; Tréluyer JM; Benaboud S; Oualha M
    Antimicrob Agents Chemother; 2022 Dec; 66(12):e0113522. PubMed ID: 36342152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum β-lactam concentrations in critically ill patients with cirrhosis: a matched case-control study.
    Lheureux O; Trepo E; Hites M; Cotton F; Wolff F; Surin R; Creteur J; Vincent JL; Gustot T; Jacobs F; Taccone FS
    Liver Int; 2016 Jul; 36(7):1002-10. PubMed ID: 26645828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of piperacillin and tazobactam in plasma and subcutaneous interstitial fluid in critically ill patients receiving continuous venovenous haemodiafiltration.
    Varghese JM; Jarrett P; Boots RJ; Kirkpatrick CM; Lipman J; Roberts JA
    Int J Antimicrob Agents; 2014 Apr; 43(4):343-8. PubMed ID: 24612982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis.
    Roberts JA; Kirkpatrick CM; Roberts MS; Dalley AJ; Lipman J
    Int J Antimicrob Agents; 2010 Feb; 35(2):156-63. PubMed ID: 20018492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repeated Piperacillin-Tazobactam Plasma Concentration Measurements in Severely Obese Versus Nonobese Critically Ill Septic Patients and the Risk of Under- and Overdosing.
    Jung B; Mahul M; Breilh D; Legeron R; Signe J; Jean-Pierre H; Uhlemann AC; Molinari N; Jaber S
    Crit Care Med; 2017 May; 45(5):e470-e478. PubMed ID: 28240688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of piperacillin/tazobactam in critically ill young children.
    Cies JJ; Shankar V; Schlichting C; Kuti JL
    Pediatr Infect Dis J; 2014 Feb; 33(2):168-73. PubMed ID: 23907263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of piperacillin in critically ill children including those undergoing continuous kidney replacement therapy.
    Butragueño-Laiseca L; Marco-Ariño N; Troconiz IF; Grau S; Campillo N; García X; Padilla B; Fernández SN; Slöcker M; Santiago MJ
    Clin Microbiol Infect; 2022 Sep; 28(9):1287.e9-1287.e15. PubMed ID: 35390523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics and pharmacodynamics of piperacillin in critically ill patients during the early phase of sepsis.
    Sukarnjanaset W; Jaruratanasirikul S; Wattanavijitkul T
    J Pharmacokinet Pharmacodyn; 2019 Jun; 46(3):251-261. PubMed ID: 30963365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Towards model-informed precision dosing of piperacillin: multicenter systematic external evaluation of pharmacokinetic models in critically ill adults with a focus on Bayesian forecasting.
    Greppmair S; Brinkmann A; Roehr A; Frey O; Hagel S; Dorn C; Marsot A; El-Haffaf I; Zoller M; Saller T; Zander J; Schatz LM; Scharf C; Briegel J; Minichmayr IK; Wicha SG; Liebchen U
    Intensive Care Med; 2023 Aug; 49(8):966-976. PubMed ID: 37439872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive performance of multi-model approaches for model-informed precision dosing of piperacillin in critically ill patients.
    Schatz LM; Greppmair S; Kunzelmann AK; Starp J; Brinkmann A; Roehr A; Frey O; Hagel S; Dorn C; Zoller M; Scharf C; Wicha SG; Liebchen U
    Int J Antimicrob Agents; 2024 Oct; 64(4):107305. PubMed ID: 39146997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. OTAC: Optimization of Antibiotic Therapy in Critically ill Patients. Using beta-lactam antibiotics by continuous infusion.
    Esteve-Pitarch E; Padullés-Zamora A; Maisterra-Santos K; Colom-Codina H; Cobo-Sacristán S
    Farm Hosp; 2019 Sep; 43(5):151-157. PubMed ID: 31469627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose optimization of piperacillin/tazobactam in critically ill children.
    De Cock PAJG; van Dijkman SC; de Jaeger A; Willems J; Carlier M; Verstraete AG; Delanghe JR; Robays H; Vande Walle J; Della Pasqua OE; De Paepe P
    J Antimicrob Chemother; 2017 Jul; 72(7):2002-2011. PubMed ID: 28387840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pilot study on pharmacokinetic/pharmacodynamic target attainment in critically ill patients receiving piperacillin/tazobactam.
    Martínková J; Malbrain ML; Havel E; Šafránek P; Bezouška J; Kaška M
    Anaesthesiol Intensive Ther; 2016; 48(1):23-8. PubMed ID: 26588478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.